Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP2-24495 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Rabbit Polyclonal Aiolos/IKZF3 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified.
- Reactivity
- Human, Simian
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Light-induced control of protein destruction by opto-PROTAC.
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Selective degradation of splicing factor CAPERα by anticancer sulfonamides.
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA
Leukemia 2020 Jun;34(6):1588-1598
Leukemia 2020 Jun;34(6):1588-1598
Light-induced control of protein destruction by opto-PROTAC.
Liu J, Chen H, Ma L, He Z, Wang D, Liu Y, Lin Q, Zhang T, Gray N, Kaniskan HÜ, Jin J, Wei W
Science advances 2020 Feb;6(8):eaay5154
Science advances 2020 Feb;6(8):eaay5154
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, Ahmann JM, de Campos CB, Braggio E, Bergsagel PL, Stewart AK
Blood cancer journal 2019 Feb 11;9(2):19
Blood cancer journal 2019 Feb 11;9(2):19
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Gao S, Geng C, Song T, Lin X, Liu J, Cai Z, Cang Y
The Journal of biological chemistry 2017 Mar 3;292(9):3683-3691
The Journal of biological chemistry 2017 Mar 3;292(9):3683-3691
Selective degradation of splicing factor CAPERα by anticancer sulfonamides.
Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, Kamiyama H, Takahashi K, Kotake Y, Uesugi M, Yokoi A, Inoue A, Yoshida T, Mabuchi M, Tanaka A, Owa T
Nature chemical biology 2017 Jun;13(6):675-680
Nature chemical biology 2017 Jun;13(6):675-680
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.
Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N
Oncotarget 2017 Aug 8;8(32):53053-53067
Oncotarget 2017 Aug 8;8(32):53053-53067
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
Nguyen TV, Li J, Lu CJ, Mamrosh JL, Lu G, Cathers BE, Deshaies RJ
Proceedings of the National Academy of Sciences of the United States of America 2017 Apr 4;114(14):3565-3571
Proceedings of the National Academy of Sciences of the United States of America 2017 Apr 4;114(14):3565-3571
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK
Blood 2014 Jul 24;124(4):536-45
Blood 2014 Jul 24;124(4):536-45
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Aiolos/IKZF3 Antibody [NBP2-24495] - Total protein from Jurkat cells and human tonsil was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-IkZF3 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Aiolos/IKZF3 Antibody [NBP2-24495] - Analysis of IKZF3 in human spleen lysate in the 1) absence and 2) presence of immunizing peptide using this antibody at 0.25 ug/mL.